Bosentan for Treatment of Pediatric Idiopathic Pulmonary Arterial Hypertension: State-of-the-Art

被引：7
|
作者：
Wang, Yuchen [1 ,2 ]
Chen, Selena [3 ]
Du, Junbao [1 ,4 ]
机构：
[1] Peking Univ, Hosp 1, Dept Pediat, Beijing, Peoples R China
[2] Peking Univ, Hlth Sci Ctr, Dept Clin Med, Beijing, Peoples R China
[3] Univ Calif San Diego, Div Biol Sci, La Jolla, CA 92093 USA
[4] Minist Educ, Key Lab Mol Cardiovasc Sci, Beijing, Peoples R China
来源：
FRONTIERS IN PEDIATRICS | 2019年 / 7卷
基金：
北京市自然科学基金;
关键词：
idiopathic pulmonary hypertension; target therapy; bosentan; pediatrics; pharmacology; CHILDREN; THERAPY; SURVIVAL; SILDENAFIL; SAFETY; PHARMACOKINETICS; EPOPROSTENOL; FORMULATION; EXPRESSION; EXPERIENCE;
D O I：
10.3389/fped.2019.00302
中图分类号：
R72 [儿科学];
学科分类号：
100202 ;
摘要：
Idiopathic pulmonary arterial hypertension (IPAH) is a complex disease associated with progressive deterioration. Targeted therapy for IPAH has improved in the last several decades. However, there remain many challenges to current treatment of children with IPAH, including poor prognosis and a median survival of 0.8 years. Endothelin-1 (ET-1) appears to be a key mediator in the pathogenesis of IPAH, with elevated concentrations in the plasma. Bosentan, an endothelin receptor antagonist, has been confirmed in Food and Drug Administration (FDA) to effectively treat IPAH when administered in recent studies. This review focuses on related studies and advance of bosentan in the treatment of IPAH in children.
引用
收藏
页数：10
相关论文
共 50 条
  • [1] Bosentan in Pediatric Patients with Pulmonary Arterial Hypertension
    Beghetti, Maurice
    CURRENT VASCULAR PHARMACOLOGY, 2009, 7 (02) : 225 - 233
  • [2] Cost-utility of ambrisentan and bosentan for pediatric pulmonary arterial hypertension
    Buendia, Jefferson Antonio
    Patino, Diana Guerrero
    Lindarte, Erika Fernanda
    EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH, 2023, 23 (08) : 967 - 973
  • [3] Bosentan: In pediatric patients with pulmonary arterial hypertension
    Carter N.J.
    Keating G.M.
    Pediatric Drugs, 2010, 12 (1) : 63 - 73
  • [4] Pharmacokinetics of Bosentan in Routinely Treated Japanese Pediatric Patients with Pulmonary Arterial Hypertension
    Taguchi, Masato
    Ichida, Fukiko
    Hirono, Keiichi
    Miyawaki, Toshio
    Yoshimura, Naoki
    Nakamura, Tsuneyuki
    Akita, Chisato
    Nakayama, Tomotaka
    Saji, Tsutomu
    Kato, Yuya
    Horiuchi, Isao
    Hashimoto, Yukiya
    DRUG METABOLISM AND PHARMACOKINETICS, 2011, 26 (03) : 280 - 287
  • [5] Idiopathic Pulmonary Arterial Hypertension in Childhood
    Haworth, Sheila G.
    CARDIOLOGY IN REVIEW, 2010, 18 (02) : 64 - 66
  • [6] Combination therapy with bosentan and sildenafil in idiopathic pulmonary arterial hypertension
    Hoeper, MM
    Faulenbach, C
    Golpon, H
    Winkler, J
    Welte, T
    Niedermeyer, J
    EUROPEAN RESPIRATORY JOURNAL, 2004, 24 (06) : 1007 - 1010
  • [7] Bosentan for the treatment of pulmonary arterial hypertension
    Kenyon, KW
    Nappi, JM
    ANNALS OF PHARMACOTHERAPY, 2003, 37 (7-8) : 1055 - 1062
  • [8] Long-term efficacy of bosentan in treatment of pulmonary arterial hypertension in children
    Hislop, A. A.
    Moledina, S.
    Foster, H.
    Schulze-Neick, I.
    Haworth, S. G.
    EUROPEAN RESPIRATORY JOURNAL, 2011, 38 (01) : 70 - 77
  • [9] Management of Pulmonary Arterial Hypertension in the Pediatric Patient
    Ezekian, Jordan E.
    Hill, Kevin D.
    CURRENT CARDIOLOGY REPORTS, 2019, 21 (12)
  • [10] Pulmonary arterial hypertension treatment with bosentan in pediatric patients with congenital heart disease
    Romero Jimenez, Rosa M.
    Garcia Sanchez, Raquel
    Gimenez Manzorro, Alvaro
    Martinez Fernandez-Llamazares, Cecilia
    Sanjurjo Saez, Maria
    PHARMACY WORLD & SCIENCE, 2009, 31 (02): : 347 - 347
12345